⚡ Quick Answer — What is Tavin EM?
Tavin EM bevat tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg and is used for HIV pre-exposure prophylaxis (PrEP) — prevention of HIV-1 infection in HIV-negative adults at substantial risk. When taken daily with high adherence, TDF/FTC-based PrEP reduces HIV infection risk by >99% when taken daily with high adherence (iPrEx, PROUD, Partners PrEP). Manufactured by Emcure Pharmaceuticals. Specialist-supervised; requires HIV-negative status confirmed before starting and every 3 months on therapy.
📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.
Waarom bestellen bij MedsBase
Wat Is Acivir 200 DT? Reshipment Assurance Policy.
Tavin EM is een daily HIV pre-exposure prophylaxis (PrEP) tablet combining tenofovir disoproxil fumarate 300 mg en emtricitabine 200 mg — the same two antiretroviral molecules that make up the brand-name Truvada® originally developed by Gilead Sciences. Manufactured by Emcure Pharmaceuticals — an Indian antiretroviral specialist with extensive HIV-medication portfolio and global tender supply relationships.
Taken consistently by HIV-negative adults at substantial risk of exposure, TDF/FTC-based PrEP reduces the risk of acquiring HIV-1 by over 99% (iPrEx open-label extension, PROUD, Partners PrEP). Missing more than one or two doses per week meaningfully reduces protection, so PrEP is fundamentally an adherence intervention as much as a pharmacological one.
What Is Tavin EM?
Tavin EM is a fixed-dose combination tablet of two nucleoside reverse transcriptase inhibitors (NRTIs):
- Tenofovir disoproxil fumarate (TDF) 300 mg — blocks HIV reverse transcriptase, preventing the virus from integrating into host DNA
- Emtricitabine (FTC) 200 mg — a cytidine analogue that likewise inhibits reverse transcriptase, with a complementary resistance profile to TDF
Used as PrEP, the two drugs pre-load HIV-negative cells with inhibitor so that any incoming virus from a sexual or injection exposure is unable to establish a productive infection. The combination is also licensed for HIV-1 treatment (as part of a 3-drug regimen) and for chronic hepatitis B, though this page focuses on PrEP use.
Clinical equivalence: Tavin EM, branded Truvada, Tenvir-EM, Tenof-EM, Tavin-EM, and Ricovir-EM all contain the same fixed-dose combination of TDF 300 mg + FTC 200 mg. Bioequivalence between manufacturers is established by drug-regulatory bodies through pharmacokinetic equivalence testing. The choice between them is primarily about manufacturer, supply, and cost — not clinical outcome.
How Tavin EM Works as PrEP
When taken daily, tenofovir and emtricitabine reach steady-state concentrations in blood, genital mucosa, and rectal tissue. When exposure to HIV happens — during unprotected sex, shared injection equipment, or mucosal contact with infected fluids — the drug is already present inside uninfected cells and blocks the virus’s reverse transcriptase step before it can integrate into host DNA and establish a chronic infection.
Key pharmacokinetic points that affect protection:
- Rectal tissue concentration reaches protective levels after approximately 7 dagen of daily dosing. This is why daily PrEP is effective quickly for men who have sex with men
- Cervicovaginal tissue concentration reaches protective levels more slowly — approximately 20–21 days of daily dosing. Women, transgender men, and anyone with vaginal or frontal sex need longer adherence before full protection
- Tenofovir has a long intracellular half-life — roughly 4–5 days. Missing a single dose does not immediately abolish protection, but skipping multiple doses per week does
- Tail cover after stopping exposure: continue dosing for at least 28 days after the last potential HIV exposure to cover the incubation window
Before Starting PrEP — Mandatory Tests
PrEP requires confirmed HIV-negative status under specialist supervision. The following baseline tests are mandatory before your first dose. Starting PrEP without confirming HIV-negative status can drive HIV drug resistance if you are already infected — with consequences for your future treatment options.
| Test | Why It Matters | Timing |
|---|---|---|
| HIV test (4th-generation antigen/antibody or HIV RNA) | Must be confirmed negative. If HIV-positive and given PrEP, the 2-drug regimen is sub-therapeutic and selects for HIV resistance mutations (M184V, K65R) | Within 7 days of starting |
| Hepatitis B-oppervlakteantigeen (HBsAg) | Tenofovir/emtricitabine also treats HBV. In HBV-positive patients, discontinuing PrEP can cause a severe hepatitis flare. HBV-positive patients require liver specialist involvement | Baseline |
| Nierfunctie (creatinine, eGFR) | TDF is cleared renally and can cause dose-dependent renal toxicity. eGFR <60 mL/min is typically a contraindication to TDF-based PrEP (consider TAF-based alternatives instead) | Baseline, then every 6 months |
| STI screen (syphilis, chlamydia, gonorrhoea) | PrEP prevents HIV, not other STIs. Baseline + quarterly screening is standard of care | Baseline, every 3 months |
| Pregnancy test (if applicable) | TDF/FTC is category B and considered safe in pregnancy, but documentation matters | Baseline |
Retest timeline: HIV test repeated every 3 months while on PrEP. Renal function every 6 months. STI screen every 3 months. Any of these being out-of-range can require a pause in PrEP.
Dosing Options
| Protocol | Who It Is For | Regime |
|---|---|---|
| Daily PrEP (first-line) | All at-risk adults: cisgender men, cisgender women, transgender people, injection drug users | 1 tablet daily, taken at the same time each day |
| Event-based / 2-1-1 (“on-demand”) dosing | Cisgender MSM only — strong evidence from IPERGAY and Prevenir trials. NOT recommended for cisgender women, transgender women, or anyone with vaginal/frontal sex because drug concentrations in vaginal/rectal tissue differ | 2 tablets 2–24 hours before sex, 1 tablet 24 hours after the first pair, 1 tablet 48 hours after the first pair. For continued exposure, continue 1 daily until 2 days after the last sexual exposure |
| Daily ramp-up (protective levels) | Men having receptive anal sex | ~7 days of daily dosing to reach protective rectal tissue concentrations |
| Daily ramp-up (protective levels, vaginal) | Women, transgender men having vaginal/frontal sex | ~21 days of daily dosing to reach protective cervicovaginal tissue concentrations. Adherence below this threshold significantly reduces effectiveness |
Key clinical nuance: PrEP is not instant protection. Daily dosing must be taken consistently, and time-to-protection depends on tissue compartment (faster for rectal tissue than cervicovaginal). Missing more than 1–2 doses per week significantly reduces efficacy.
Bijwerkingen
Most side effects occur in the first 2–4 weeks (“start-up syndrome”) and resolve with continued use.
| Ernst | Bijwerking |
|---|---|
| Common, transient (first 2–4 weeks) | Nausea, diarrhoea, abdominal discomfort, headache, fatigue. Usually resolves without intervention |
| Less common | Dizziness, rash, decreased appetite, weight loss, insomnia |
| Dose-dependent (long-term monitoring) | Mild reduction in bone mineral density (reversible on stopping), small decline in renal function (reversible in most men) |
| Zeldzaam maar ernstig | Acute renal failure (Fanconi syndrome), lactic acidosis, severe liver enzyme elevation, hepatic steatosis. Seek urgent medical attention for severe fatigue, unexplained muscle pain, persistent nausea, or jaundice |
| HBV-specific (if HBV-positive) | Stopping TDF/FTC in an HBV-positive patient can trigger an acute hepatitis flare — potentially life-threatening. HBV-positive patients on PrEP must not stop suddenly without hepatologist involvement |
Contraindications and Precautions
- Confirmed HIV-positive status — TDF/FTC is a 2-drug regimen that is sub-therapeutic for HIV treatment; using it selects for resistance mutations that compromise future treatment
- Severe renal impairment (eGFR <60 mL/min) — TDF requires a functioning kidney; TAF-based PrEP is an alternative for eGFR 30–59
- Concurrent nephrotoxic drugs — aminoglycosides, high-dose NSAIDs, IV contrast, adefovir, cidofovir. Review with a clinician before combining
- Acute hepatitis — use caution and consult a hepatologist
- Borstvoeding — tenofovir is secreted in breast milk. Risk/benefit assessment with a clinician is advised if the infant is HIV-negative and there are other HIV-prevention options
Geneesmiddelinteracties
- Nefrotoxische geneesmiddelen (aminoglycosides, amphotericin B, cidofovir, IV pentamidine, high-dose or chronic NSAIDs) — additive renal toxicity
- Didanosine (ddI) — increased didanosine exposure and toxicity; avoid combining
- Ledipasvir/sofosbuvir (Harvoni) — raises tenofovir exposure. Generally manageable with renal monitoring but clinician review recommended
- Adefovir — same drug class, do not combine
- HIV post-exposure prophylaxis (PEP) regimens — if PEP is prescribed after a high-risk exposure while on PrEP, the regimens are managed together by an HIV specialist
How to Take — Practical Guidance
- Swallow the tablet whole with water, at the same time each day. Consistency is what makes PrEP work — missing more than 1–2 doses per week meaningfully reduces protection
- Can be taken with or without food. If nausea is a problem in the first weeks, taking with food helps
- If a dose is missed and remembered within 24 hours, take it as soon as remembered. If more than 24 hours have passed, skip the missed dose and continue with the next scheduled one — do not double up
- Do not stop PrEP suddenly if you are HBV-positive — contact your clinician first
- After the last sexual exposure, continue PrEP for at least 28 days (2-dose tail) to cover any virus in the incubation period
Opslag
- Store below 30°C in a cool, dry place
- Bewaar in de originele blisterverpakking tot gebruik
- Niet gebruiken na de vervaldatum die op de verpakking staat vermeld
- Buiten bereik van kinderen en huisdieren houden
Tavin EM vs Branded Truvada, TAF-based PrEP, and Other Generics
| Option | Ingredients | Kidney/Bone Safety | Sex-Specific Efficacy Data | Cost Tier |
|---|---|---|---|---|
| Tavin EM (this product) | TDF 300 + FTC 200 | Standard TDF monitoring | All exposures (vaginal + anal + injection) | Lowest |
| Tenvir EM (Cipla) | TDF 300 + FTC 200 | Standard TDF monitoring | All exposures | Low |
| Branded Truvada® (Gilead) | TDF 300 + FTC 200 | Standard TDF monitoring | All exposures | Highest |
| Tenvir AF / Descovy® | TAF 25 + FTC 200 | Significantly gentler on kidneys and bone mineral density | Licensed for MSM and transgender women only — trial data for cis-women incomplete | Matig |
Which should you pick? If you have normal renal function and no bone-density concerns, TDF/FTC (the product on this page) is first-line in every major guideline (CDC, WHO, BHIVA, IAS-USA). If you have eGFR 30–59 mL/min, osteoporosis, or other reasons to avoid TDF, TAF-based PrEP (Tenvir AF / Descovy) is safer but only approved for anal-sex HIV exposure routes. Discuss your specific situation with an HIV-prescribing clinician.
Related PrEP Options
- Tenvir EM — Cipla generic Truvada (largest Indian manufacturer, WHO-prequalified)
- Tenvir AF — Cipla generic Descovy (TAF-based, gentler on kidneys and bone)
- Ricovir EM — Mylan generic Truvada
- Tenof EM — Hetero generic Truvada
- SOA-beschermingspakket — TDF/FTC + doxycycline + azithromycin sexual-health stack
Zie ook: comprehensive Tenvir EM page (our most-referenced TDF/FTC product), and the broader HIV-medicatie en Seksuele gezondheid categories.
Veelgestelde vragen
Is Tavin EM the same as Truvada?
Clinically equivalent. Tavin EM contains exactly the same active ingredients as Truvada (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg) and is produced to pharmaceutical bioequivalence standards. The clinical evidence supporting PrEP is based on these two molecules, so the protection delivered by a bioequivalent generic is the same as the original brand.
How effective is Tavin EM at preventing HIV?
TDF/FTC-based PrEP reduces HIV-1 acquisition by over 99% in people who maintain high adherence (at least 4 doses per week for men who have sex with men; daily dosing for cisgender women and trans men). The highest-quality evidence comes from the iPrEx, PROUD, and Partners PrEP randomised controlled trials.
How long does it take to become protected?
It depends on the exposure route. For rectal HIV exposure (anal sex), daily dosing reaches protective tissue levels in approximately 7 dagen. For cervicovaginal exposure (vaginal/frontal sex), approximately 20–21 days of daily dosing is needed. For the on-demand 2-1-1 protocol (cisgender MSM only), the first double-dose provides acute pharmacological cover.
Do I need to see a doctor before starting?
Yes. PrEP requires confirmed HIV-negative status under specialist supervision before starting. Starting PrEP while unknowingly HIV-positive can cause drug resistance that limits future HIV treatment. You also need baseline kidney-function, HBV, and STI testing. Every 3 months you need repeat HIV and STI screening; every 6 months, renal function.
Can I take Tavin EM only when I think I’ll need it?
Voor cisgender men who have sex with men, the “2-1-1” (event-based) protocol has strong trial evidence (IPERGAY, Prevenir). For cisgender women, transgender women, and anyone with vaginal/frontal sex, on-demand dosing is not recommended — tissue pharmacokinetics differ and daily dosing is required for reliable protection.
Wat gebeurt er als ik stop met innemen?
If you are HIV-negative and HBV-negative, you can stop safely after completing a 28-day tail following your last HIV exposure. If you are HBV-positive, do not stop without clinician involvement — abrupt TDF discontinuation in chronic HBV can trigger an acute hepatitis flare.
Will PrEP protect me from other STIs?
Nee. PrEP prevents HIV only. You still need condoms, vaccinations (HPV, HepA, HepB if not immune), and quarterly STI screening for chlamydia, gonorrhoea, and syphilis. See our SOA-beschermingspakket for a broader sexual-health medication stack including DoxyPEP.
Does Tavin EM have side effects?
Most men experience mild nausea, headache, or diarrhoea in the first 2–4 weeks (“start-up syndrome”), which resolves with continued use. Long-term, TDF causes a small reduction in bone mineral density and a minor decline in renal function — both usually reversible on stopping. Serious renal toxicity (Fanconi syndrome, acute renal failure) is rare but requires urgent medical attention.
Can I combine Tavin EM with other medications?
Yes, most medications. Avoid concurrent nephrotoxic drugs (aminoglycosides, high-dose NSAIDs, cidofovir, adefovir). Most routine medications including hormonal contraception, SSRIs, statins, PDE5 inhibitors, and antibiotics are safe. Always disclose PrEP to your prescriber.
Is Tavin EM available without a prescription?
Nee. PrEP is a specialist-supervised regimen that requires baseline HIV-negative status confirmation, kidney-function and HBV testing, and follow-up every 3 months. Do not start PrEP without a clinician confirming HIV-negative status and baseline safety tests.
What is the “2-1-1” on-demand protocol?
The event-based regimen studied in the IPERGAY trial: 2 tablets taken 2–24 hours before anticipated sex, 1 tablet 24 hours after the first dose, and 1 tablet 48 hours after the first dose. If sex continues, continue 1 tablet daily until 48 hours after the last exposure. Evidence supports this protocol in cisgender MSM only.
Tavin-EM users adding bacterial-STI protection to their PrEP regimen can switch to our PrEP Starter Pack (Tenvir-EM + doxycycline 100 mg) — TDF/FTC for HIV and doxycycline 100 mg for CDC-endorsed doxy-PEP, layered protection in one bundled order.
Those using Tavin EM for PrEP who wish to compare sourcing options should note that Tenvir EM (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg) contains the same WHO-approved TDF/FTC combination and is produced to equivalent WHO-GMP quality standards by Cipla.
Patiënten op Tavin EM (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg) who require an NNRTI anchor are often progressed to a complete fixed-dose combination such as Avonza (TDF / lamivudine / efavirenz), eliminating the need for a separate third agent.
Beide Tavin-EM en Taficita (TAF 25 mg + emtricitabine 200 mg) provide daily oral PrEP; Taficita’s tenofovir alafenamide base is the modern choice where long-term kidney safety matters.
Andere Seksuele Gezondheidsmedicijnen
- Tenvir EM (TDF/FTC 300+200 mg)
- Ricovir EM (TDF/FTC 300+200 mg)
- Tenof EM (TDF/FTC 300+200 mg)
- Taficita (TAF/FTC 25+200 mg, generieke Descovy)
- SOA-beschermingspakket
Medische disclaimer: De informatie op deze pagina is alleen voor educatieve doeleinden en vervangt geen medisch advies. Raadpleeg altijd een gekwalificeerde arts voordat u begint, stopt of wijzigt met medicatie.

































